Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEG-Man nanovaccine
- Development stage
- Preclinical
- Lead developer
- Universidade de Lisboa
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
**PEG-Man nanovaccine** is an experimental mannose-targeted poly(ethylene glycol)-poly(lactic-co-glycolic acid) nanoparticle cancer vaccine evaluated in immunocompetent murine solid-tumor models. The formulation uses mannose surface modification to promote uptake by dendritic cells through the mannose receptor CD206 and is designed to deliver peptide antigens together with immune adjuvants and immune-modulating payloads. In the reported AACR 2025 study, PEG-Man nanovaccine produced weaker antigen-specific T-cell responses and less tumor-growth inhibition than the corresponding polyoxazoline-mannose nanovaccine comparator. It has no reported clinical development, regulatory approval, marketed brand, or assigned INN.
- Other names
- PEG-mannose nanovaccine
02
Targets
MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on PEG-Man nanovaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEG-Man nanovaccine.